Recursion Pharma

Recursion Pharma

A clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.

  • Edit
DateInvestorsAmountRound
-

N/A

-

N/A

Spinout

$100k

Seed
N/A

$200k

Seed

N/A

Debt
N/A

$800k

Debt

$1.5m

Grant
N/A

$2.7m

Debt

$12.9m

Series A

$2.2m

Series A

$4.0m

Debt
*

$60.0m

Series B

$20.5m

Debt

$121m

Series C

$239m

Valuation: $1.0b

293.0x EV/Revenue

-12.4x EV/EBITDA

Series D
N/A

$436m

Valuation: $2.7b

270.0x EV/Revenue

-14.8x EV/EBITDA

IPO
*

$150m

Private Placement VC
*

$50.0m

Post IPO Equity
*
N/A

$200m

Post IPO Equity
Total Funding$587m

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2021202220232024202520262027
Revenues0000000000000000000000000000
% growth193 %297 %11 %33 %28 %29 %119 %
EBITDA0000000000000000000000000000
% EBITDA margin(1828 %)(619 %)(701 %)(730 %)(821 %)(517 %)(173 %)
Profit0000000000000000000000000000
% profit margin(1865 %)(604 %)(748 %)(793 %)(850 %)(523 %)(82 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue1353 %392 %550 %538 %---

Source: Company filings or news article, Equity research estimates

Notes (0)
More about Recursion Pharma
Made with AI
Edit

Recursion Pharmaceuticals is a next-generation biopharmaceutical company that leverages advanced technology to decode biology and radically improve lives. The company operates in the TechBio sector, utilizing a combination of hardware, software, and data to industrialize drug discovery. Recursion's core service involves creating virtuous cycles of learning around vast datasets, which include 50 petabytes of proprietary biological, chemical, and patient-centric data. This data is used to profile genes and compounds through up to 2.2 million weekly wet lab experiments, producing 50 cell types at scale, including 1 trillion hiPSC-derived neuronal cells. The company also boasts a top 500 supercomputer, BioHive 1, to process these datasets and generate 6 trillion gene and compound relationships in their Maps.

Recursion serves a diverse range of clients, including pharmaceutical companies, research institutions, and healthcare providers. The company operates on a business model that focuses on strategic partnerships and collaborations, which are some of the most significant in the TechBio industry. Recursion makes money through these partnerships, as well as through the development and commercialization of new drugs discovered using their proprietary technology.

Keywords: biopharmaceutical, TechBio, drug discovery, datasets, gene profiling, wet lab experiments, supercomputer, cell types, strategic partnerships, commercialization.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Recursion Pharma

Edit
Cyclica
ACQUISITION by Recursion Pharma May 2023
Exscientia
ACQUISITION by Recursion Pharma Aug 2024
Vium
ACQUISITION by Recursion Pharma Jul 2020
Valence Discovery
ACQUISITION by Recursion Pharma May 2023